YEAR-END REPORT 1 JANUARY

Episurf Medical reported modest quarterly and annual improvements in revenue and order intake—Q4 gross order intake SEK 3.5m (3.1), Q4 net sales SEK 3.5m (3.4), quarter loss SEK -13.5m (-18.1) and EPS -0.01 (-0.03); full-year gross order intake SEK 14.8m (13.0), net sales SEK 13.5m (13.0), loss SEK -58.2m (-76.0) and EPS -0.06 (-0.16). The company announced a major strategic pivot into real estate with an acquisition structure of up to SEK 1,147m partly financed by shares, convertibles and warrants (first closing completed; properties agreed at SEK 897m), alongside ongoing US market progress (65% order intake growth, 120% increase in US customer base) and continued FDA-related work on the Episealer MTP implant. The transaction and financing are material and dilutive, representing a significant corporate transformation that could materially affect capital structure and investor valuation while near-term operations show improving but still loss-making fundamentals.

Analysis

Market structure: Episurf’s move converts a micro-cap medtech story into a hybrid real‑estate/operator with an acquisition package (up to SEK 1,147m) that dwarfs 2025 revenue (SEK 13.5m) and annual losses (SEK -58m). Winners: counterparties to the property seller, Swedish REITs/landlords (re-rating tailwind to local real estate multiples) and holders of newly issued convertibles if property yields are stable; losers: existing EPIS B equity holders facing immediate dilution and potential strategic drift. Cross-asset: expect equity sell pressure in EPIS B, higher implied equity vols, SEK liquidity flows into domestic real estate names and limited impact on broader credit/commodities beyond Sweden property curves.

Risk assessment: Tail risks include FDA rejection or a clinical setback for Episealer® MTP (0–25% probability within 6–12 months) and failure to finance the acquisition leading to forced asset sales or covenant breaches. Immediate (days) risk is share-price compression around EGM/first-closing; short-term (weeks–months) risk is dilution through share/convertible issuance; long-term (quarters–years) risk is misallocation of capital away from high‑margin medtech growth. Hidden dependencies: financing tranches, board composition changes, and potential cross-collateralization of medical assets for real‑estate debt.

Trade implications: Primary direct play is negative on EPIS B equity and implied vol — initiate a calibrated short or buy puts around near-term EGM and rights‑issue windows (next 30–90 days). Pair trade: short EPIS B vs long large-cap Swedish REITs (e.g., CAST‑B) to isolate strategy risk; use option spreads (buy 3‑month 10% OTM puts, sell 3‑month 30% OTM puts) to limit capital. Timing: act pre‑EGM and pre‑rights‑issue announcement; trim if FDA clears MTP within 6 months or if dilution <15% and management commits to non‑dilutive financing.

Contrarian angles: Consensus underprices the upside if management successfully stabilizes cash flow and retains the medtech narrative — a successful integration could re-rate EPIS B by 30–80% over 12–36 months, but that requires disciplined, non‑dilutive execution. Reaction may be overdone in the near term if market panics over headline acquisition size; a tactical covered-call buy on a 12‑month horizon could capture mean reversion if dilution is limited. Historical parallel: small biotech pivoting to real estate usually destroys value absent strong governance — monitor governance changes and convertible economics as the decisive signal.

Key Decisions for Investors

• Establish a tactical 2–3% portfolio short position in EPIS B (ticker EPIS B) via borrowed shares or buy 3‑month put spreads: buy 10% OTM puts and sell 30% OTM puts (cost‑reduced) sized to net 2–3% exposure; set stop‑loss at a 30% adverse move and reassess at EGM and rights‑issue pricing.
• Implement a pair trade: short EPIS B (as above) and simultaneously go long 2–4% in large‑cap Swedish REITs to capture potential rerating of domestic property (example exposure: CAST‑B (Castellum) or FABG‑B (Fabege)); rebalance if property NAV disclosure shows >10% accretion to EPIS’s pro‑forma balance sheet.
• Purchase a conditional, event‑driven long: buy 9–12 month call spreads on EPIS B (buy 100% spot strike, sell 150% strike) sized 1–2% of portfolio that are activated only if FDA provides positive guidance or clears the MTP implant within the next 6 months.
• Set concrete monitoring triggers for position sizing: increase short exposure by another 2% if announced dilution/exchangeable securities exceed 15% of current market cap or if convertible terms include forced conversion within 12 months; reduce short to zero if dilution is <8% and company secures ≥3 years of non‑dilutive debt at <5% real yields.